Cancer invasion and resistance: interconnected processes of disease progression and therapy failure.

[1]  奈々 佐々木.  Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression , 2013 .

[2]  Rakesh K Jain,et al.  Delivery of molecular and cellular medicine to solid tumors. , 1997, Advanced drug delivery reviews.

[3]  Stephanie Alexander,et al.  Cancer Invasion and the Microenvironment: Plasticity and Reciprocity , 2011, Cell.

[4]  M. Quinn,et al.  Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell‐like profile , 2011, Journal of cellular biochemistry.

[5]  J. Santibañez,et al.  TGF-β/TGF-β receptor system and its role in physiological and pathological conditions. , 2011, Clinical science.

[6]  Yi Zheng,et al.  Cdc42 in oncogenic transformation, invasion, and tumorigenesis. , 2011, Cellular signalling.

[7]  L. Gaboury,et al.  CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti‐VEGF treatment or docetaxel in a transgenic mouse model , 2011, International journal of cancer.

[8]  N. Cordes,et al.  Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  P. Carmeliet,et al.  Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? , 2011, Nature Reviews Clinical Oncology.

[10]  W. You,et al.  VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. , 2011, Cancer research.

[11]  Shailesh Singh,et al.  CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion , 2011, World journal of surgical oncology.

[12]  P. Pollock,et al.  Targeting mutant fibroblast growth factor receptors in cancer. , 2011, Trends in molecular medicine.

[13]  Frank McCormick,et al.  Cancer therapy based on oncogene addiction , 2011, Journal of surgical oncology.

[14]  Shailesh Singh,et al.  CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion. , 2011, International journal of oncology.

[15]  H. Weiss,et al.  mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. , 2011, Cancer research.

[16]  E. Medico,et al.  Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. , 2011, Journal of the National Cancer Institute.

[17]  Gregory F Weber,et al.  Integrins and cadherins join forces to form adhesive networks , 2011, Journal of Cell Science.

[18]  F. Sotgia,et al.  Autophagy drives compartment‐specific oncogenesis: HIF1‐alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells , 2011 .

[19]  M. Duffy,et al.  Use of molecular markers for predicting therapy response in cancer patients. , 2011, Cancer treatment reviews.

[20]  K. Koike,et al.  New targeted therapies for gastric cancer , 2011, Expert opinion on investigational drugs.

[21]  M. Zöller.  CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? , 2011, Nature Reviews Cancer.

[22]  J. Yates,et al.  Integrin αβ1, αvβ, α6β effectors p130Cas, Src and talin regulate carcinoma invasion and chemoresistance. , 2011, Biochemical and biophysical research communications.

[23]  Ann Richmond,et al.  Chemokines in health and disease. , 2011, Experimental cell research.

[24]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[25]  K. M. Chen,et al.  Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma , 2011, Clinical Cancer Research.

[26]  Caroline Dive,et al.  Circulating tumor cells as a window on metastasis biology in lung cancer. , 2011, The American journal of pathology.

[27]  O. Pardo,et al.  The catalytic class I(A) PI3K isoforms play divergent roles in breast cancer cell migration. , 2011, Cellular signalling.

[28]  R. Jain,et al.  CXCL12 (SDF1α)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies? , 2011, Clinical Cancer Research.

[29]  H. Nagai,et al.  Blockade of CXCR4 in oral squamous cell carcinoma inhibits lymph node metastases. , 2011, European journal of cancer.

[30]  M. Washington,et al.  Combined Blockade of Src Kinase and Epidermal Growth Factor Receptor with Gemcitabine Overcomes STAT3-Mediated Resistance of Inhibition of Pancreatic Tumor Growth , 2011, Clinical Cancer Research.

[31]  Karen H. Vousden,et al.  p53 and its mutants in tumor cell migration and invasion , 2011, The Journal of cell biology.

[32]  E. Tartour,et al.  Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy , 2011, Cancer and Metastasis Reviews.

[33]  P. Chavrier,et al.  Contractility of the cell rear drives invasion of breast tumor cells in 3D Matrigel , 2011, Proceedings of the National Academy of Sciences.

[34]  S. Fuqua,et al.  Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. , 2011, Cancer research.

[35]  Alexander D. MacKerell,et al.  Small‐Molecule Inhibitors of the ERK Signaling Pathway: Towards Novel Anticancer Therapeutics , 2011, ChemMedChem.

[36]  D. Hess,et al.  Migratory strategies of normal and malignant stem cells. , 2011, Methods in molecular biology.

[37]  Xin Lu,et al.  Prognostic role of systemic inflammatory response in renal cell carcinoma: a systematic review and meta-analysis , 2011, Journal of Cancer Research and Clinical Oncology.

[38]  A. Mackensen,et al.  Suppression of T-cell responses by tumor metabolites , 2011, Cancer Immunology, Immunotherapy.

[39]  L. Coussens,et al.  The Tumor-Immune Microenvironment and Response to Radiation Therapy , 2010, Journal of Mammary Gland Biology and Neoplasia.

[40]  A. Frey,et al.  Tumor-Induced Disruption of Proximal TCR-Mediated Signal Transduction in Tumor-Infiltrating CD8+ Lymphocytes Inactivates Antitumor Effector Phase , 2010, The Journal of Immunology.

[41]  D. Banerjee,et al.  Interleukin 6 mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu. , 2010, Experimental cell research.

[42]  D. Silasi,et al.  High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. , 2010, American journal of obstetrics and gynecology.

[43]  L. Trusolino,et al.  MET signalling: principles and functions in development, organ regeneration and cancer , 2010, Nature Reviews Molecular Cell Biology.

[44]  David A. Cheresh,et al.  Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.

[45]  S. Niclou,et al.  αB-crystallin is elevated in highly infiltrative apoptosis-resistant glioblastoma cells. , 2010, The American journal of pathology.

[46]  Venkat Maruthamuthu,et al.  Conserved F-actin dynamics and force transmission at cell adhesions. , 2010, Current opinion in cell biology.

[47]  Luke A. Gilbert,et al.  DNA Damage-Mediated Induction of a Chemoresistant Niche , 2010, Cell.

[48]  J. Soria,et al.  The Role of Anti–Epidermal Growth Factor Receptor and Anti-Vascular Endothelial Growth Factor Therapies in the Treatment of Non-Small-Cell Lung Cancer , 2010 .

[49]  Paola Chiarugi,et al.  Rac and Rho GTPases in cancer cell motility control , 2010, Cell Communication and Signaling.

[50]  Klaus Pantel,et al.  Circulating tumour cells in cancer patients: challenges and perspectives. , 2010, Trends in molecular medicine.

[51]  F. Sotgia,et al.  HIF1-alpha functions as a tumor promoter in cancer-associated fibroblasts, and as a tumor suppressor in breast cancer cells , 2010, Cell cycle.

[52]  J. Settleman,et al.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer , 2010, Oncogene.

[53]  N. Altorki,et al.  TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer , 2010, Proceedings of the National Academy of Sciences.

[54]  S. Motoyama,et al.  The CRP 1846T/T genotype is associated with a poor prognosis in patients with non-small cell lung cancer , 2010, Tumor Biology.

[55]  F. Garrido,et al.  “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy , 2010, International journal of cancer.

[56]  C. Pilarsky,et al.  PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha. , 2010, The Journal of clinical investigation.

[57]  A. Puisieux,et al.  TWISTing an embryonic transcription factor into an oncoprotein , 2010, Oncogene.

[58]  M. Georgescu,et al.  Invasive glioblastoma cells acquire stemness and increased Akt activation. , 2010, Neoplasia.

[59]  Agnieszka K Witkiewicz,et al.  The reverse Warburg Effect: Glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts , 2010, Cell cycle.

[60]  J. S. Rao,et al.  Effects of irradiation on tumor cell survival, invasion and angiogenesis , 2010, Journal of Neuro-Oncology.

[61]  Gerhard Christofori,et al.  Mechanisms of Motility in Metastasizing Cells , 2010, Molecular Cancer Research.

[62]  J. Bertrand,et al.  A New α5β1 Integrin-Dependent Survival Pathway Through GSK3β Activation in Leukemic Cells , 2010, PloS one.

[63]  Y. Xu,et al.  A common gain of function of p53 cancer mutants in inducing genetic instability , 2010, Oncogene.

[64]  Charles P. Lin,et al.  Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. , 2010, Blood.

[65]  J. Greenwood,et al.  The RhoA Activator GEF-H1/Lfc Is a Transforming Growth Factor-β Target Gene and Effector That Regulates α-Smooth Muscle Actin Expression and Cell Migration , 2010, Molecular biology of the cell.

[66]  P. Friedl,et al.  The Journal of Cell Biology , 2002 .

[67]  E. Repasky,et al.  Hypoxia-driven immunosuppression: A new reason to use thermal therapy in the treatment of cancer? , 2010, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[68]  H. Lenz,et al.  EGFR Signaling and Drug Discovery , 2010, Oncology.

[69]  R. Karlsson,et al.  Rho GTPase function in tumorigenesis. , 2009, Biochimica et biophysica acta.

[70]  A. Pintzas,et al.  Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. , 2009, Biochimica et biophysica acta.

[71]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[72]  A. Gazdar,et al.  Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. , 2009, Cancer research.

[73]  E. Haura,et al.  Src kinases as therapeutic targets for cancer , 2009, Nature Reviews Clinical Oncology.

[74]  Olga Ilina,et al.  Mechanisms of collective cell migration at a glance , 2009, Journal of Cell Science.

[75]  Robert A. Gatenby,et al.  Environment-mediated drug resistance: a major contributor to minimal residual disease , 2009, Nature Reviews Cancer.

[76]  K. Shokat,et al.  Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. , 2009, Blood.

[77]  Victoria Sanz-Moreno,et al.  Rho-GTPase signaling drives melanoma cell plasticity , 2009, Cell cycle.

[78]  Massimo Libra,et al.  PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches , 2009, Cell cycle.

[79]  Stephen J. Weiss,et al.  Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited , 2009, The Journal of cell biology.

[80]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[81]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[82]  M. Goppelt‐Struebe,et al.  Connective tissue growth factor: Context‐dependent functions and mechanisms of regulation , 2009, BioFactors.

[83]  R. Jove,et al.  Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. , 2009, Cancer research.

[84]  C. Schnell,et al.  PI3K inhibitors for cancer treatment: where do we stand? , 2009, Biochemical Society transactions.

[85]  Paul D. P. Pharoah,et al.  p53 polymorphisms: cancer implications , 2009, Nature Reviews Cancer.

[86]  Colin K. Choi,et al.  Integrins in cell migration – the actin connection , 2009, Journal of Cell Science.

[87]  P. Kelly,et al.  Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. , 2009, Journal of neurosurgery.

[88]  E. Bosco,et al.  Rac1 GTPase: A “Rac” of All Trades , 2009, Cellular and Molecular Life Sciences.

[89]  Peter Friedl,et al.  Proteolytic interstitial cell migration: a five-step process , 2009, Cancer and Metastasis Reviews.

[90]  T. Meyer,et al.  Modular control of endothelial sheet migration. , 2008, Genes & development.

[91]  M. Celeste Simon,et al.  The impact of O2 availability on human cancer , 2008, Nature Reviews Cancer.

[92]  Olivier De Wever,et al.  Stromal myofibroblasts are drivers of invasive cancer growth , 2008, International journal of cancer.

[93]  Stephanie Alexander,et al.  Dynamic imaging of cancer growth and invasion: a modified skin-fold chamber model , 2008, Histochemistry and Cell Biology.

[94]  E. Sahai,et al.  Rac Activation and Inactivation Control Plasticity of Tumor Cell Movement , 2008, Cell.

[95]  P. Allavena,et al.  Macrophage polarization in tumour progression. , 2008, Seminars in cancer biology.

[96]  M. Silverstein,et al.  Invasive local recurrence increased after radiation therapy for ductal carcinoma in situ. , 2008, American journal of surgery.

[97]  R. Kerbel,et al.  Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. , 2008, Cancer cell.

[98]  S. Fulda,et al.  Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells , 2008, Oncogene.

[99]  Anne J. Ridley,et al.  Mammalian Rho GTPases: new insights into their functions from in vivo studies , 2008, Nature Reviews Molecular Cell Biology.

[100]  V. Bronte,et al.  Myeloid-derived suppressor cell role in tumor-related inflammation. , 2008, Cancer letters.

[101]  M. Slomiany,et al.  Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. , 2008, Seminars in cancer biology.

[102]  P. Harari,et al.  Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members , 2008, Oncogene.

[103]  C. Nakaseko,et al.  CD44 and hyaluronan engagement promotes dexamethasone resistance in human myeloma cells , 2008, European journal of haematology.

[104]  F. Bertucci,et al.  Defining the molecular biology of inflammatory breast cancer. , 2008, Seminars in oncology.

[105]  野村 悟.  FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer , 2008 .

[106]  N. Hanna,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2008 .

[107]  E. Hirsch,et al.  Isoform selective phosphoinositide 3-kinase gamma and delta inhibitors and their therapeutic potential. , 2008, Recent patents on inflammation & allergy drug discovery.

[108]  G. Robertson,et al.  Is B-Raf a good therapeutic target for melanoma and other malignancies? , 2008, Cancer research.

[109]  J. Clements,et al.  Epithelial—mesenchymal and mesenchymal—epithelial transitions in carcinoma progression , 2007, Journal of cellular physiology.

[110]  G. Gallick,et al.  Development and Characterization of Gemcitabine-Resistant Pancreatic Tumor Cells , 2007, Annals of Surgical Oncology.

[111]  Erik Sahai,et al.  Illuminating the metastatic process , 2007, Nature Reviews Cancer.

[112]  M. Stack,et al.  Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion , 2007, Nature Cell Biology.

[113]  H. Kajiyama,et al.  Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. , 2007, International journal of oncology.

[114]  M. Bissell,et al.  Ionizing radiation predisposes nonmalignant human mammary epithelial cells to undergo transforming growth factor beta induced epithelial to mesenchymal transition. , 2007, Cancer research.

[115]  C. Prives,et al.  Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? , 2007, Oncogene.

[116]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[117]  Catherine C. Park,et al.  beta1 integrin as a molecular therapeutic target , 2007, International journal of radiation biology.

[118]  P. Gierschik,et al.  Oncogenic K-Ras down-regulates Rac1 and RhoA activity and enhances migration and invasion of pancreatic carcinoma cells through activation of p38. , 2006, Cellular signalling.

[119]  L. Ellis,et al.  Chronic Oxaliplatin Resistance Induces Epithelial-to-Mesenchymal Transition in Colorectal Cancer Cell Lines , 2006, Clinical Cancer Research.

[120]  J. Grandis,et al.  STAT3 is required but not sufficient for EGF receptor-mediated migration and invasion of human prostate carcinoma cell lines , 2006, British Journal of Cancer.

[121]  L. Cantley,et al.  Ras, PI(3)K and mTOR signalling controls tumour cell growth , 2006, Nature.

[122]  D. Lauffenburger,et al.  Protein kinase Cδ signaling downstream of the EGF receptor mediates migration and invasiveness of prostate cancer cells , 2006 .

[123]  Peter Friedl,et al.  Molecular mechanisms of cancer cell invasion and plasticity , 2006, The British journal of dermatology.

[124]  Walter Birchmeier,et al.  Balancing cell adhesion and Wnt signaling, the key role of β-catenin , 2006 .

[125]  D. Lauffenburger,et al.  Protein kinase Cdelta signaling downstream of the EGF receptor mediates migration and invasiveness of prostate cancer cells. , 2006, Biochemical and biophysical research communications.

[126]  Walter Birchmeier,et al.  Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. , 2006, Current opinion in genetics & development.

[127]  K. Golen,et al.  The current understanding of the molecular determinants of inflammatory breast cancer metastasis , 2006, Clinical & Experimental Metastasis.

[128]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[129]  M. Nieto,et al.  The Snail genes as inducers of cell movement and survival: implications in development and cancer , 2005, Development.

[130]  V. P. Eswarakumar,et al.  Cellular signaling by fibroblast growth factor receptors. , 2005, Cytokine & growth factor reviews.

[131]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[132]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[133]  A. Reynolds,et al.  Emerging roles for p120-catenin in cell adhesion and cancer , 2004, Oncogene.

[134]  J. Pollard,et al.  A Paracrine Loop between Tumor Cells and Macrophages Is Required for Tumor Cell Migration in Mammary Tumors , 2004, Cancer Research.

[135]  F. Balkwill,et al.  The chemokine network in cancer--much more than directing cell movement. , 2004, The International journal of developmental biology.

[136]  Baolin Zhang,et al.  Rac1 Inhibits Apoptosis in Human Lymphoma Cells by Stimulating Bad Phosphorylation on Ser-75 , 2004, Molecular and Cellular Biology.

[137]  Rameen Beroukhim,et al.  Molecular characterization of the tumor microenvironment in breast cancer. , 2004, Cancer cell.

[138]  P. M. Campbell,et al.  Oncogenic Ras and its role in tumor cell invasion and metastasis. , 2004, Seminars in cancer biology.

[139]  Michael E. Berens,et al.  Glioma Cell Motility is Associated with Reduced Transcription of Proapoptotic and Proliferation Genes: A cDNA Microarray Analysis , 2001, Journal of Neuro-Oncology.

[140]  P. Houghton,et al.  Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. , 2003, Cancer research.

[141]  D. Coppola,et al.  Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway. , 2003, Cancer research.

[142]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[143]  Paul Dent,et al.  MAPK pathways in radiation responses , 2003, Oncogene.

[144]  Erik Sahai,et al.  Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis , 2003, Nature Cell Biology.

[145]  I. Fidler,et al.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.

[146]  P. Friedl,et al.  Tumour-cell invasion and migration: diversity and escape mechanisms , 2003, Nature Reviews Cancer.

[147]  Nils Cordes,et al.  Cell Adhesion-Mediated Radioresistance (CAM-RR) Extracellular Matrix-Dependent Improvement of Cell Survival in Human Tumor and Normal Cells in Vitro , 2003, Strahlentherapie und Onkologie.

[148]  M. Westphal,et al.  Cost of migration: invasion of malignant gliomas and implications for treatment. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[149]  P. Comoglio,et al.  Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.

[150]  B. Anachkova,et al.  Nucleotide excision repair rates in rat tissues. , 2003, European journal of biochemistry.

[151]  Peter Friedl,et al.  Compensation mechanism in tumor cell migration , 2003, The Journal of cell biology.

[152]  J. Downward.  Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.

[153]  Richard O Hynes,et al.  Integrins Bidirectional, Allosteric Signaling Machines , 2002, Cell.

[154]  Y. Hegerfeldt,et al.  Collective cell movement in primary melanoma explants: plasticity of cell-cell interaction, beta1-integrin function, and migration strategies. , 2002, Cancer research.

[155]  M. Blagosklonny.  Oncogenic resistance to growth-limiting conditions , 2002, Nature Reviews Cancer.

[156]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[157]  E. Rovida,et al.  Transmodulation of Cell Surface Regulatory Molecules via Ectodomain Shedding , 2002, Biological chemistry.

[158]  M. Gottesman.  Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.

[159]  T. Mak,et al.  Regulation of PTEN transcription by p53. , 2001, Molecular cell.

[160]  C. Beaudry,et al.  Death-associated protein 3 (Dap-3) is overexpressed in invasive glioblastoma cells in vivo and in glioma cell lines with induced motility phenotype in vitro. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[161]  R. Jain.  Delivery of molecular and cellular medicine to solid tumors. , 2001, Advanced drug delivery reviews.

[162]  J. Vasiliev,et al.  Changes in p53 expression in mouse fibroblasts can modify motility and extracellular matrix organization , 2000, Oncogene.

[163]  M. Westphal,et al.  Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. , 2000, Neoplasia.

[164]  E. Rosen,et al.  The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3′ kinase , 2000, Oncogene.

[165]  K. Mokbel,et al.  The effect of surgical wounding on tumour development. , 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[166]  K. Kinzler,et al.  Genetic instability and darwinian selection in tumours. , 1999, Trends in cell biology.

[167]  K. Nabeshima,et al.  Cohort migration of carcinoma cells: differentiated colorectal carcinoma cells move as coherent cell clusters or sheets. , 1999, Histology and histopathology.

[168]  E. Bröcker,et al.  Functional hierarchy of simultaneously expressed adhesion receptors: integrin alpha2beta1 but not CD44 mediates MV3 melanoma cell migration and matrix reorganization within three-dimensional hyaluronan-containing collagen matrices. , 1999, Molecular biology of the cell.

[169]  L. Schwartz,et al.  Recurrent gallbladder carcinoma along laparoscopic cholecystectomy port tracks: CT demonstration. , 1999, Radiology.

[170]  W. Faught,et al.  Port site recurrences following laparoscopically managed early stage endometrial cancer. , 1999, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[171]  W. Dalton,et al.  Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines , 1999 .

[172]  K. Vousden,et al.  Mechanisms of p53-mediated apoptosis , 1999, Cellular and Molecular Life Sciences CMLS.

[173]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[174]  A. Ganser,et al.  Exposure to vinblastine modulates beta 1 integrin expression and in vitro binding to extracellular matrix molecules in a human renal carcinoma cell line. , 1996, Invasion & metastasis.

[175]  P. Friedl,et al.  Migration of coordinated cell clusters in mesenchymal and epithelial cancer explants in vitro. , 1995, Cancer research.

[176]  Bonnie F. Sloane,et al.  Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. , 1994, Cancer research.

[177]  S. Lelièvre,et al.  Development and characterization of suramin-resistant Chinese hamster fibrosarcoma cells: drug-dependent formation of multicellular spheroids and a greatly enhanced metastatic potential. , 1994, Cancer research.

[178]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[179]  J. Kuszak,et al.  Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. , 1991, Cancer research.

[180]  P. Devreotes,et al.  Chemotaxis in eukaryotic cells: a focus on leukocytes and Dictyostelium. , 1988, Annual review of cell biology.